This partnership
is personal

Genomic solutions to change how cancer will be identified and treated

Future of NGS in Oncology

As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.

Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that can make a significant impact on the field of oncology in the future. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.

This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.

NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.

Oncology
Introduction to NGS for Oncologists

Learn more about NGS technology and the role it might play in clinical oncology in the future.

Read Introduction
Introduction to NGS for Oncologists

Featured Oncology Stories

 
Chinese Collaboration to Develop Cancer Tests on Illumina System
Chinese Collaboration to Develop Cancer Tests on Illumina System

AnchorDx to focus on early cancer detection and clinical management panels

Read Article
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories

Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.

Read Interview
TruSight Oncology 500 Selected to Power Liquid Biopsy Studies
TruSight Oncology 500 Selected to Power Liquid Biopsy Studies

Illumina to collaborate with the Frederick National Laboratory for Cancer Research

Read Article
Image
Genomic Applications in Oncology

The Medical Affairs team at Illumina discusses the applications of genomics in oncology for risk prediction and precision medicine.

Learn More
The Changing Landscape of NGS in Oncology
The Changing Landscape of NGS in Oncology

Key opinion leaders discuss the ongoing challenges and potential of NGS in molecular diagnostics.

Read Interview
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up
Genomics Powers Access to Cancer Breakthroughs
Genomics Powers Access to Cancer Breakthroughs

Garret Hampton, EVP of Clinical Genomics at Illumina, shares his vision for how genomics might shape the future of oncology.

Read Interview
Image
Medical Genetics Education

Find educational resources about medical genetics and learn how genomic information can be used in clinical practice.

Learn More